A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients

Gastroenterology

Volumn 129, Issue 4, 2005, Pages 1198-1209

  Chang, Ting Tsung ^a,k   Gish, Robert G ^b   Hadziyannis, Stephanos J ^c   Cianciara, Janusz ^d   Rizzetto, Mario ^e   Schiff, Eugene R ^f   Pastore, Giuseppe ^g   Bacon, Bruce R ^h   Poynard, Thierry ⁱ   Joshi, Shobha ^j,l   Klesczewski, Kenneth S ^j   Thiry, Alexandra ^j   Rose, Ronald E ^j   Colonno, Richard J ^j   Hindes, Robert G ^j  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c HENRY DUNANT HOSPITAL   (Greece)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF MIAMI   (United States)

^g UNIVERSITY OF BARI   (Italy)

^h SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^k NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^l TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LIVER ENZYME; VIRUS DNA;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CHROMATURIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPOGLYCEMIA; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VIREMIA;

EID: 26844500312     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2005.06.055     Document Type: Article

References (53)

1. W.M. Lee Hepatitis B virus infection N Engl J Med 337 1997 1733 1745
2. World Health Organization Fact sheet WHO/204. Hepatitis B 2003 World Health Organization Geneva, Switzerland October 9
3. Hepatitis B fact sheet 2004 National Center for Infectious Diseases, Centers for Disease Control and Prevention Atlanta, GA December 8
4. K. Krogsgaard, N. Bindslev, E. Christensen, A. Craxi, P. Schlichting, S. Schalm, V. Carreno, C. Trepo, G. Gerken, H.C. Thomas The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep) J Hepatol 21 1994 646 655
5. J.L. Dienstag, E.R. Schiff, T.L. Wright, R.P. Perrillo, H.W. Hann, Z. Goodman, L. Crowther, L.D. Condreay, M. Woessner, M. Rubin, N.A. Brown Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1999 1256 1263
6. F. Nevens, J. Main, P. Honkoop, D.L. Tyrrell, J. Barber, M.T. Sullivan, J. Fevery, R.A. De Man, H.C. Thomas Lamivudine therapy for chronic hepatitis B a six-month randomized dose-ranging study Gastroenterology 113 1997 1258 1263
7. S.W. Schalm, J. Heathcote, J. Cianciara, G. Farrell, M. Sherman, B. Willems, A. Dhillon, A. Moorat, J. Barber, D.F. Gray Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection a randomised trial Gut 46 2000 562 568
8. Y.F. Liaw Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B Antivir Chem Chemother 12 2001 67 71
9. S.K. Ono, N. Kato, Y. Shiratori, J. Kato, T. Goto, R.F. Schinazi, F.J. Carrilho, M. Omata The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance J Clin Invest 107 2001 449 455
10. F. Zoulim Detection of hepatitis B virus resistance to antivirals J Clin Virol 21 2001 243 253
11. D.T. Lau, M.F. Khokhar, E. Doo, M.G. Ghany, D. Herion, Y. Park, D.E. Kleiner, P. Schmid, L.D. Condreay, J. Gauthier, M.C. Kuhns, T.J. Liang, J.H. Hoofnagle Long-term therapy of chronic hepatitis B with lamivudine Hepatology 32 2000 828 834
12. L.J. Stuyver, S.A. Locarnini, A. Lok, D.D. Richman, W.F. Carman, J.L. Dienstag, R.F. Schinazi Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region Hepatology 33 2001 751 757
13. M.I. Allen, M. Deslauriers, C.W. Andrews, G.A. Tipples, K.A. Walters, D.L. Tyrrell, N. Brown, L.D. Condreay Lamivudine Clinical Investigation Group Identification and characterization of mutations in hepatitis B virus resistant to lamivudine Hepatology 27 1998 1670 1677
14. H.G. Niesters, P. Honkoop, E.B. Haagsma, R.A. De Man, S.W. Schalm, A.D. Osterhaus Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment J Infect Dis 177 1998 1382 1385
15. G.V. Papatheodoridis, E. Dimou, V. Papadimitropoulos Nucleoside analogues for chronic hepatitis B antiviral efficacy and viral resistance Am J Gastroenterol 97 2002 1618 1628
16. D. Mutimer Hepatitis B virus infection resistance to antiviral agents J Clin Virol 21 2001 239 242
17. Y.H. Paik, H.Y. Chung, W.S. Ryu, K.S. Lee, J.S. Lee, J.H. Kim, C.K. Lee, C.Y. Chon, Y.M. Moon, K.H. Han Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea J Hepatol 35 2001 92 98
18. Y.F. Liaw, R.N. Chien, C.T. Yeh, S.L. Tsai, C.M. Chu Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy Hepatology 30 1999 567 572
19. A. Ayres, A. Bartholomeusz, G. Lau, K.C. Lam, J.Y. Lee, S. Locarnini Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure J Clin Virol 27 2003 111 116
20. M. Bonacini, A. Kurz, S. Locarnini, A. Ayres, C. Gibbs Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV Gastroenterology 122 2002 244 245
21. J.W. Kim, H.S. Lee, G.H. Woo, J.H. Yoon, J.J. Jang, J.G. Chi, C.Y. Kim Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate- aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy Clin Infect Dis 33 2001 403 405
22. P. Honkoop, R.A. De Man, H.G. Niesters, P.E. Zondervan, S.W. Schalm Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy Hepatology 32 2000 635 639
23. H. Fontaine, F. Driss, J.L. Lagneau Hepatitis B virus reactivation after lamivudine discontinuation (abstr) Hepatology 30 1999 349A
24. B.C. Song, D.J. Suh, H.C. Lee, Y.H. Chung, Y.S. Lee Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 32 2000 803 806
25. A.S. Lok, C.L. Lai, N. Leung, G.B. Yao, Z.Y. Cui, E.R. Schiff, J.L. Dienstag, E.J. Heathcote, N.R. Little, D.A. Griffiths, S.D. Gardner, M. Castiglia Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1722
26. Y.F. Liaw, R.N. Chien, C.T. Yeh No benefit to continue lamivudine therapy after emergence of YMDD mutations Antivir Ther 9 2004 257 262
27. S.F. Innaimo, M. Seifer, G.S. Bisacchi, D.N. Standring, R. Zahler, R.J. Colonno Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus Antimicrob Agents Chemother 41 1997 1444 1448
28. N. Tanji, K. Tanji, N. Kambham, G.S. Markowitz, A. Bell, V.D. D'Agati Adefovir nephrotoxicity possible role of mitochondrial DNA depletion Hum Pathol 32 2001 734 740
29. D.J. Tenney, S.M. Levine, R.E. Rose, A.W. Walsh, S.P. Weinheimer, L. Discotto, M. Plym, K. Pokornowski, C.F. Yu, P. Angus, A. Ayres, A. Bartholomeusz, W. Sievert, G. Thompson, N. Warner, S. Locarnini, R.J. Colonno Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine Antimicrob Agents Chemother 48 2004 3498 3507
30. S. Levine, D. Hernandez, G. Yamanaka, S. Zhang, R. Rose, S. Weinheimer, R.J. Colonno Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro Antimicrob Agents Chemother 46 2002 2525 2532
31. R.J. Colonno, E.V. Genovesi, I. Medina, L. Lamb, S.K. Durham, M.L. Huang, L. Corey, M. Littlejohn, S. Locarnini, B.C. Tennant, B. Rose, J.M. Clark Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection J Infect Dis 184 2001 1236 1245
32. E.V. Genovesi, L. Lamb, I. Medina, D. Taylor, M. Seifer, S. Innaimo, R.J. Colonno, D.N. Standring, J.M. Clark Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection Antimicrob Agents Chemother 42 1998 3209 3217
33. P.L. Marion, F.H. Salazar, M.A. Winters, R.J. Colonno Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication Antimicrob Agents Chemother 46 2002 82 88
34. R.A. De Man, L.M. Wolters, F. Nevens, D. Chua, M. Sherman, C.L. Lai, A. Gadano, Y. Lee, F. Mazzotta, N. Thomas, D. Dehertogh Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection Hepatology 34 2001 578 582
35. C.L. Lai, M. Rosmawati, J. Lao, H. Van Vlierberghe, F.H. Anderson, N. Thomas, D. Dehertogh Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection Gastroenterology 123 2002 1831 1838
36. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S.G. Lim, Z. Goodman, M.S. Wulfsohn, S. Xiong, J. Fry, C.L. Brosgart Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B N Engl J Med 348 2003 800 807
37. K. Chayama, Y. Suzuki, M. Kobayashi, M. Kobayashi, A. Tsubota, M. Hashimoto, Y. Miyano, H. Koike, M. Kobayashi, I. Koida, Y. Arase, S. Saitoh, N. Murashima, K. Ikeda, H. Kumada Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy Hepatology 27 1998 1711 1716
38. R.A. De Man, A.I. Bartholomeusz, H.G. Niesters, P.E. Zondervan, S.A. Locarnini The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss J Hepatol 29 1998 669 675
39. P. Honkoop, H.G. Niesters, R.A. De Man, A.D. Osterhaus, S.W. Schalm Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns J Hepatol 26 1997 1393 1395
40. C.L. Lai, R.N. Chien, N.W. Leung, T.T. Chang, R. Guan, D.I. Tai, K.Y. Ng, P.C. Wu, J.C. Dent, J. Barber, S.L. Stephenson, D.F. Gray Asia Hepatitis Lamivudine Study Group A one-year trial of lamivudine for chronic hepatitis B N Engl J Med 339 1998 61 68
41. C.L. Lai Antiviral therapy for hepatitis B and C in Asians J Gastroenterol Hepatol 14 Suppl 1999 S19 S21
42. B.C. Song, D.J. Suh, H.C. Lee Seroconversion after lamivudine treatment is not durable in chronic hepatitis B (abstr) Hepatology 30 1999 348A
43. M.G. Peters, H.H. Hann, P. Martin, E.J. Heathcote, P. Buggisch, R. Rubin, M. Bourliere, K. Kowdley, C. Trepo, D.D. Gray, M. Sullivan, K. Kleber, R. Ebrahimi, S. Xiong, C.L. Brosgart Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 2004 91 101
44. E.R. Schiff, C.L. Lai, S. Hadziyannis, P. Neuhaus, N. Terrault, M. Colombo, H.L. Tillmann, D. Samuel, S. Zeuzem, L. Lilly, M. Rendina, J.P. Villeneuve, N. Lama, C. James, M.S. Wulfsohn, H. Namini, C. Westland, S. Xiong, G.S. Choy, S. Van Doren, J. Fry, C.L. Brosgart Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients Hepatology 38 2003 1419 1427
45. H. Izzedine, J.S. Hulot, V. Launay-Vacher, P. Marcellini, S.J. Hadziyannis, G. Currie, C.L. Brosgart, C. Westland, S. Arterbrun, G. Deray Renal safety of adefovir dipivoxil in patients with chronic hepatitis B two double-blind, randomized, placebo-controlled studies Kidney Int 66 2004 1153 1158
46. M.M. Bartholomew, R.W. Jansen, L.J. Jeffers, K.R. Reddy, L.C. Johnson, H. Bunzendahl, L.D. Condreay, A.G. Tzakis, E.R. Schiff, N.A. Brown Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation Lancet 349 1997 20 22
47. M. Buti, R. Jardi, M. Cotrina, F. Rodriguez-Frias, R. Esteban, J. Guardia Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine J Hepatol 28 1998 510 513
48. R. Ling, D. Mutimer, M. Ahmed, E.H. Boxall, E. Elias, G.M. Dusheiko, T.J. Harrison Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine Hepatology 24 1996 711 713
49. C. Boni, A. Bertoletti, A. Penna, A. Cavalli, M. Pilli, S. Urbani, P. Scognamiglio, R. Boehme, R. Panebianco, F. Fiaccadori, C. Ferrari Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B J Clin Invest 102 1998 968 975
50. S. Nair, R.P. Perrillo Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 34 2001 1021 1026
51. Hepsera 2002 Gilead Sciences Foster City, CA [prescribing information]
52. M.R. Brunetto, M. Giarin, G. Saracco, F. Oliveri, P. Calvo, G. Capra, A. Randone, M.L. Abate, P. Manzini, M. Capalbo Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B Gastroenterology 105 1993 845 850
53. N.C. Tassopoulos, R. Volpes, G. Pastore, J. Heathcote, M. Buti, R.D. Goldin, S. Hawley, J. Barber, L. Condreay, D.F. Gray Lamivudine Precore Mutant Study Group Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B Hepatology 29 1999 889 896